Contact this trialFirst, we need to learn more about you.
Antibiotic
Rifaximin for Monoclonal Gammopathy
Recruiting3 awardsPhase 1
Atlanta, Georgia
This trial studies how well rifaximin, an oral antibiotic, works in treating patients with monoclonal gammopathy. It aims to reduce abnormal blood proteins or cells by killing intestinal bacteria. Rifaximin has been used successfully for CDI treatment but lacks United States Food and Drug Administration approval for this indication.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service